Universal Biosensors Management

Management criteria checks 2/4

Universal Biosensors' CEO is Peter Mullin, appointed in Dec 2024, has a tenure of less than a year. directly owns 0.85% of the company’s shares, worth A$147.36K. The average tenure of the management team and the board of directors is 2.3 years and 8.8 years respectively.

Key information

Peter Mullin

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.9%
Management average tenure	2.3yrs
Board average tenure	8.8yrs

Recent management updates

Recent updates

CEO

Peter Mullin (55 yo)

less than a year

Tenure

Mr. Peter Mullin is Chief Financial Officer of Universal Biosensors, Inc. from December 18, 2024 and serves as its Director since January 15, 2025. He serves as Finance Director at Universal Biosensors, In...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Salesh Balak	Company Secretary & Corporate Advisor	6.3yrs	AU$250.70k	0.13% A$ 22.5k
Peter Mullin	MD, CEO	less than a year	no data	0.85% A$ 147.4k
Keith Sims	Global Marketing Director	1.3yrs	no data	no data
Anthony Soha	Head of Sales	1.3yrs	no data	no data
Luke Cossins	Head of Research & Development	4.3yrs	no data	no data
Ann Chew	Head of People Strategy & Culture	3.3yrs	no data	no data

2.3yrs

Average Tenure

Experienced Management: UBI's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Peter Mullin	MD, CEO	less than a year	no data	0.85% A$ 147.4k
Craig Coleman	Non-Executive Director	8.8yrs	AU$86.33k	0.33% A$ 56.3k
David Hoey	Independent Non-Executive Director	9.1yrs	AU$77.60k	0.22% A$ 38.4k
Judith Smith	Independent Non-Executive Director	10.1yrs	AU$86.33k	0.15% A$ 25.7k
Graham McLean	Independent Non-Executive Chairman	3.1yrs	AU$114.14k	0.36% A$ 62.6k
David Church	Member of the Scientific Advisory Panel	no data	no data	no data
John Loftus	Member of the Scientific Advisory Panel	no data	no data	no data
Simon Corrie	Member of the Scientific Advisory Panel	no data	no data	no data
Steve Kitchen	Member of the Scientific Advisory Panel	no data	no data	no data
Sam Schulman	Member of the Scientific Advisory Panel	no data	no data	no data
Davide Matino	Member of the Scientific Advisory Panel	no data	no data	no data
Eric Wilkes	Member of the Scientific Advisory Panel	no data	no data	no data

8.8yrs

Average Tenure

59yo

Average Age

Experienced Board: UBI's board of directors are considered experienced (8.8 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/04/30 11:56
End of Day Share Price	2025/04/30 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Universal Biosensors, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Tara Speranza	Bell Potter
Shane Storey	Wilsons Advisory and Stockbroking Ltd.

Universal Biosensors Management

Management criteria checks 2/4

Key information

Recent management updates

Universal Biosensors, Inc., Annual General Meeting, May 12, 2025

Universal Biosensors, Inc. Announces Company Secretary Changes

Universal Biosensors, Inc. Announces Chief Financial Officer Changes

Non-Executive Director recently bought AU$50k worth of stock

Universal Biosensors, Inc., Annual General Meeting, May 30, 2024

Universal Biosensors, Inc., Annual General Meeting, Apr 10, 2024

Recent updates

Universal Biosensors, Inc., Annual General Meeting, May 12, 2025

Universal Biosensors, Inc. Announces Company Secretary Changes

Universal Biosensors, Inc. Announces Chief Financial Officer Changes

New minor risk - Share price stability

Third quarter 2024 earnings released: AU$0.011 loss per share (vs AU$0.012 loss in 3Q 2023)

New minor risk - Share price stability

Universal Biosensors, Inc. to Report First Half, 2024 Results on Aug 09, 2024

Second quarter 2024 earnings released: AU$0.014 loss per share (vs AU$0.007 profit in 2Q 2023)

Non-Executive Director recently bought AU$50k worth of stock

First quarter 2024 earnings released: AU$0.016 loss per share (vs AU$0.018 loss in 1Q 2023)

Universal Biosensors, Inc., Annual General Meeting, May 30, 2024

New minor risk - Shareholder dilution

Universal Biosensors, Inc., Annual General Meeting, Apr 10, 2024

New minor risk - Shareholder dilution

Universal Biosensors, Inc. has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Universal Biosensors, Inc. to Report Fiscal Year 2023 Results on Mar 07, 2024

Universal Biosensors, Inc. has filed a Follow-on Equity Offering in the amount of AUD 10 million.

Universal Biosensors, Inc. has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.

New major risk - Financial position

Full year 2023 earnings released: AU$0.032 loss per share (vs AU$0.14 loss in FY 2022)

Third quarter 2023 earnings released: AU$0.012 loss per share (vs AU$0.024 loss in 3Q 2022)

New major risk - Share price stability

New minor risk - Financial position

Second quarter 2023 earnings released: EPS: AU$0.007 (vs AU$0.024 loss in 2Q 2022)

First quarter 2023 earnings released: AU$0.018 loss per share (vs AU$0.025 loss in 1Q 2022)

Full year 2022 earnings released: AU$0.14 loss per share (vs AU$0.059 loss in FY 2021)

Universal Biosensors, Inc. Launches New Product, Fructose Test for Sentia

Universal Biosensors, Inc. completes Xprecia Prime clinical trial in USA

Universal Biosensors, Inc. Announces Chairman Changes

Non-Executive Chairman recently bought AU$54k worth of stock

Third quarter 2022 earnings released: AU$0.024 loss per share (vs AU$0.016 loss in 3Q 2021)

Non-Executive Chairman recently bought AU$56k worth of stock

Second quarter 2022 earnings released: AU$0.024 loss per share (vs AU$0.01 loss in 2Q 2021)

Universal Biosensors, Inc. has completed a Follow-on Equity Offering in the amount of AUD 20.007467 million.

First quarter 2022 earnings released: AU$0.025 loss per share (vs AU$0.008 loss in 1Q 2021)

Universal Biosensors, Inc., Annual General Meeting, Jun 21, 2022

Forecast to breakeven in 2024

Universal Biosensors, Inc. Announces Interim Results from the Peter Mac Sponsored Tn Antigen Development Clinical Study

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Universal Biosensors, Inc. Announces the Launch of the Sentia Malic Acid Test into the Global Wine Market

Third quarter 2021 earnings released: AU$0.016 loss per share (vs AU$0.012 loss in 3Q 2020)

Second quarter 2021 earnings released: AU$0.01 loss per share (vs AU$0.017 loss in 2Q 2020)

First quarter 2021 earnings released: AU$0.008 loss per share (vs AU$0.008 loss in 1Q 2020)

Independent Non-Executive Director has left the company

Universal Biosensors, Inc. Announces Resignation of Marshall Heinberg as Director

New 90-day low: AU$0.39

Universal Biosensors, Inc. Enters into Non-Exclusive Distribution Agreement with Enartis Inc

New 90-day high: AU$0.57

Universal Biosensors, Inc. Releases SENTIA

New 90-day high: AU$0.34

Independent Non-Executive Director recently bought AU$62k worth of stock

Third quarter earnings released

Universal Biosensors, Inc. Announces Appointment of Promedeus s.r.o. as Its New Distribution Partner in Czech Republic and Slovak Republic

New 90-day high - AU$0.34

New 90-day high - AU$0.28

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources